5-HTP
5-Hydroxytryptophan (5-HTP) is the direct biological building block for serotonin, the primary chemical messenger that regulates mood, sleep, and satiety. By bypassing the rate-limiting enzyme for serotonin production, this amino acid readily crosses the blood-brain barrier to elevate central serotonergic activity. This direct delivery mechanism makes it a potent intervention for mood disorders, with clinical trials showing that 300 milligrams per day can produce improvements in depressive symptoms comparable to standard pharmaceuticals. Beyond emotional regulation, 5-HTP acts on the hypothalamus to suppress appetite, reliably reducing daily caloric intake by 15 to 18 percent in controlled studies. When taken in the evening at doses of 100 to 300 milligrams, it also serves as a substrate for melatonin synthesis, improving sleep architecture and duration. By directly addressing systemic serotonin deficits, 5-HTP offers a targeted metabolic strategy to preserve psychological resilience and long-term neurological health.
Key Takeaways
- •5-HTP bypasses the rate-limiting step of serotonin synthesis by entering the pathway after tryptophan hydroxylase (TPH), the enzyme subject to end-product feedback inhibition and competition from other large neutral amino acids for transport across the blood-brain barrier. Because 5-HTP is a direct substrate for aromatic L-amino acid decarboxylase (AADC/DDC), it is converted to serotonin in any tissue expressing DDC, including intestinal enterochromaffin cells, peripheral neurons, and central serotonergic neurons. The efficiency of this conversion means that significant peripheral serotonin production occurs alongside central production.
- •Supplemental 5-HTP significantly elevates both peripheral and central serotonin. Peripheral 5-HTP-derived serotonin is synthesized predominantly in the gut and enters circulation as platelet-loaded 5-HT. Central serotonin synthesis increases in raphe nucleus neurons and their projections. The net clinical effect is increased serotonergic tone across multiple physiological systems simultaneously: mood regulation, appetite suppression, sleep architecture improvement (through serotonin-melatonin conversion), pain modulation, and nausea. The breadth of serotonin effects explains both the clinical versatility of 5-HTP and its potential for adverse interactions with serotonergic medications.
- •The SLC6A4 gene (serotonin transporter, SERT) determines how efficiently synaptic serotonin is cleared after release. The well-studied 5-HTTLPR promoter polymorphism (short allele) reduces SERT expression, leaving more serotonin in the synapse for longer periods. In individuals with the short/short (SS) genotype, supplemental 5-HTP increases serotonin synthesis into a system with already-reduced clearance capacity, potentially amplifying serotonergic signaling more than in long/long (LL) individuals. This genotype-by-supplement interaction is a compelling example of nutrigenomics, where the functional consequence of supplementation is partially determined by SERT promoter variant.
- •Clinical evidence for 5-HTP in depression encompasses several small-to-medium randomized controlled trials from the 1970s through 1990s, most conducted in Europe. A 1991 double-blind trial by Poldinger et al. (Psychopathology, n=34) found 5-HTP at 300 mg per day comparable to fluvoxamine 150 mg per day over 6 weeks on the Hamilton Depression Rating Scale, with superior tolerability. A 2002 Cochrane review by Shaw et al. identified the evidence as promising but methodologically limited. The evidence is most consistent for mild-to-moderate depression and anxiety states rather than severe major depressive disorder.
- •The appetite-suppressing effect of 5-HTP is one of its most consistent and mechanistically well-understood benefits. Serotonin in the hypothalamus, particularly acting on 5-HT2C receptors on POMC (proopiomelanocortin) neurons in the arcuate nucleus, reduces appetite and increases satiety. Three RCTs by Cangiano et al. (1991, 1992, and 1998) in obese subjects found 5-HTP at 600 to 900 mg per day significantly reduced caloric intake by 15 to 18 percent, reduced carbohydrate intake preferentially, and produced 1 to 2 kg more weight loss than placebo over 6 weeks in the absence of dietary restriction.
- •Serotonin syndrome risk is the dominant safety concern for 5-HTP supplementation, arising from additive serotonergic load when 5-HTP is combined with any serotonin-modulating medication. SSRIs, SNRIs, MAOIs, triptans, tramadol, linezolid, methylene blue, and certain antihistamines all increase serotonergic tone through various mechanisms. The combination with MAOIs is absolutely contraindicated because MAOIs block serotonin degradation while 5-HTP increases serotonin synthesis, creating the potential for life-threatening serotonin excess. Concurrent SSRI or SNRI use is generally contraindicated without close physician supervision because additive serotonergic effects increase serotonin syndrome risk.
- •Peripheral decarboxylation of 5-HTP in the gut and blood is a significant pharmacokinetic challenge. Without carbidopa co-administration (a peripheral DDC inhibitor), the majority of 5-HTP is converted to serotonin before reaching the CNS, and peripheral serotonin excess causes nausea, vomiting, and diarrhea as the most common side effects. Co-administration of peripheral DDC inhibitors (carbidopa at 50 to 100 mg) or selective intestinal DDC inhibitors markedly reduces peripheral serotonin formation, improves CNS 5-HTP delivery, and reduces GI side effects. This clinical approach was validated in European trials combining 5-HTP with benserazide or carbidopa.
Basic Information
- Name
- 5-HTP
- Also Known As
- 5-hydroxytryptophan5-HTPoxitriptanL-5-HTPGriffonia seed extract
- Category
- Amino acid metabolite / serotonin precursor
- Bioavailability
- 5-HTP has approximately 70 percent oral bioavailability compared to intravenous administration, substantially higher than tryptophan. Unlike tryptophan, 5-HTP does not compete with other large neutral amino acids for transport across the blood-brain barrier because it is transported by a different mechanism; this means dietary protein intake does not reduce 5-HTP brain uptake. Peak plasma concentrations occur 1.5 to 2 hours after oral dosing. The major bioavailability challenge is significant peripheral decarboxylation by DDC in the intestinal wall and liver before systemic absorption, converting 5-HTP to serotonin that cannot enter the CNS. Co-administration of peripheral DDC inhibitors (carbidopa 50 to 100 mg) reduces this peripheral conversion and increases the fraction of 5-HTP reaching the brain.
- Half-Life
- Plasma half-life of 5-HTP is approximately 2 to 4 hours after oral dosing. The short half-life means that two to three times daily dosing is needed to maintain consistent serotonin precursor availability. Serotonin formed from 5-HTP is rapidly metabolized to 5-HIAA (5-hydroxyindoleacetic acid) by monoamine oxidase (MAO-A) and then excreted in urine; elevated urinary 5-HIAA is used as a biomarker of 5-HTP conversion to serotonin in clinical pharmacokinetic studies. The downstream melatonin synthesis route from serotonin provides a longer-duration effect on circadian function extending beyond the 5-HTP half-life.
Primary Mechanisms
Direct substrate for aromatic L-amino acid decarboxylase (AADC/DDC): converted to serotonin (5-HT) in both peripheral and central nervous system tissues
Bypasses tryptophan hydroxylase (TPH1/TPH2), the rate-limiting and feedback-regulated step in serotonin biosynthesis
Central serotonin synthesis increase in raphe nucleus neurons and their projections to cortex, limbic system, and basal ganglia
5-HT2C receptor activation on hypothalamic POMC neurons suppressing appetite and increasing satiety signaling
Serotonin precursor for melatonin synthesis via N-acetyltransferase and HIOMT in the pineal gland, supporting sleep onset
Serotonin modulation of pain pathways through descending inhibitory projections from raphe magnus
Peripheral serotonin increase in enterochromaffin cells and platelet uptake, modulating gut motility and platelet activation
Potential NMDA receptor modulation through serotonin effects on glutamatergic synaptic transmission in the prefrontal cortex
Quick Safety Summary
Clinical trials have used doses ranging from 100 mg per day (for sleep and pediatric applications) to 900 mg per day (for obesity and appetite suppression in the Cangiano trials). Depression trials typically used 200 to 300 mg per day. Migraine prevention trials used 600 mg per day. Most trials are 4 to 12 weeks in duration. Long-term safety beyond 6 months has not been rigorously studied in controlled trials. The eosinophilia-myalgia syndrome (EMS) associated with L-tryptophan contamination in 1989 to 1990 has not been definitively linked to 5-HTP itself, but surveillance for peak-X contamination (an impurity found in some 5-HTP preparations) remains relevant in product quality assessment.
Concurrent use with MAOIs (monoamine oxidase inhibitors including phenelzine, selegiline, tranylcypromine, and dietary tyramine precautions): additive serotonin accumulation creates severe serotonin toxicity risk; absolutely contraindicated, Concurrent use with SSRIs or SNRIs without physician supervision: additive serotonergic load increases serotonin syndrome risk; requires careful dose titration and monitoring if combined, Concurrent use with triptans (sumatriptan, rizatriptan, etc.) for migraine: additive serotonergic stimulation increases serotonin syndrome risk, particularly with repeated triptan doses, Carcinoid tumor: 5-HTP supplementation markedly increases peripheral serotonin production, potentially exacerbating carcinoid syndrome symptoms including flushing, diarrhea, and bronchoconstriction, Systemic mastocytosis: mast cells store and release serotonin; conditions with mast cell activation may be worsened by increased serotonin precursor availability, Pregnancy and breastfeeding: insufficient safety data; theoretical concern about serotonin's roles in fetal development including vasoconstriction and platelet function
Overview
5-Hydroxytryptophan (5-HTP) is the direct biochemical intermediate between the dietary amino acid tryptophan and the neurotransmitter serotonin (5-hydroxytryptamine, 5-HT). Endogenously, 5-HTP is produced from tryptophan by tryptophan hydroxylase-2 (TPH2) in the raphe nuclei of the brainstem for central serotonin synthesis, and by TPH1 in the gut enterochromaffin cells and pineal gland for peripheral serotonin and melatonin synthesis. As a supplement, 5-HTP is extracted from the seeds of Griffonia simplicifolia, a West African climbing shrub with seed pods containing up to 20 percent 5-HTP by dry weight. The supplement form bypasses the TPH-catalyzed step, which is both rate-limiting and subject to end-product feedback inhibition, and enters the pathway as the immediate precursor to serotonin conversion by aromatic L-amino acid decarboxylase (AADC/DDC). 5-HTP has been commercially available in Europe since the 1970s and in North America since the 1990s, with the bulk of clinical trial evidence generated in Italian and Swiss research centers.
The molecular pharmacology of 5-HTP centers on its role as a direct substrate for AADC. In serotonergic neurons of the raphe nuclei, AADC converts 5-HTP to serotonin using pyridoxal-5-phosphate (P5P, vitamin B6) as the obligate cofactor. Unlike tryptophan, which must first compete with other large neutral amino acids (valine, leucine, isoleucine, phenylalanine, tyrosine) for transport across the blood-brain barrier via the LAT1 amino acid transporter, 5-HTP crosses the blood-brain barrier efficiently through a different transport mechanism and does not compete with the dietary amino acids that are abundant after high-protein meals. This means that dietary protein intake, which reduces tryptophan brain uptake, does not impair 5-HTP brain uptake, making 5-HTP a more pharmacokinetically reliable serotonin precursor than tryptophan itself. Once inside serotonergic neurons, 5-HTP is decarboxylated to serotonin by AADC in a reaction that is not subject to the same allosteric feedback inhibition that limits TPH2 activity when intraneuronal serotonin accumulates.
Serotonin's physiological roles are extraordinarily broad, which explains the wide range of clinical applications for 5-HTP. Approximately 90 to 95 percent of the body's serotonin is produced in the gut by enterochromaffin cells, where it regulates intestinal motility, fluid secretion, and pain sensitization in the enteric nervous system. The remaining 5 to 10 percent is produced in the brain, where serotonergic projections from the dorsal and medial raphe nuclei reach virtually every brain region, influencing mood, emotion, impulse control, sleep-wake cycle, appetite, pain perception, social behavior, and memory consolidation. Serotonin is also the immediate precursor to melatonin: in the pineal gland, serotonin is converted to N-acetylserotonin by arylalkylamine N-acetyltransferase (AANAT) and then to melatonin by hydroxyindole-O-methyltransferase (HIOMT), creating the biochemical link between 5-HTP supplementation and melatonin production that underlies its sleep-promoting effects. In the hypothalamus, serotonin acting on 5-HT2C receptors on POMC neurons suppresses feeding behavior and increases satiety, a mechanism shared with the weight-loss drug lorcaserin.
The clinical evidence landscape for 5-HTP spans multiple psychiatric and neurological conditions, with the strongest evidence in depression, anxiety, appetite suppression, fibromyalgia, and migraine prevention. The methodological quality of the clinical trials is generally lower than the evidence base for pharmaceutical antidepressants: most 5-HTP trials were conducted in the 1970s through 1990s with smaller sample sizes (20 to 100 patients), shorter durations (4 to 12 weeks), and varying outcome measures. The 2002 Cochrane review of 5-HTP for depression (Shaw et al.) identified only 2 RCTs meeting methodological quality standards, both showing superiority over placebo, but concluded the evidence is insufficient for firm clinical recommendations pending larger modern trials. For appetite suppression, the three Cangiano trials are notable for consistency across replications. For fibromyalgia, the Caruso 1990 trial remains the most cited, with a 50 percent responder rate significantly exceeding the 20 percent placebo response. The evidence consistently points toward 5-HTP as a modestly effective intervention for serotonin-related conditions in medication-free individuals, with the primary clinical barrier being the serotonin syndrome risk that makes it incompatible with the most commonly prescribed psychiatric medications.
Core Health Impacts
- • Depression and mood elevation: Clinical trials from the 1970s through 1990s, predominantly European, consistently found 5-HTP superior to placebo for depression outcomes. The most rigorous comparison was the Poldinger et al. trial (1991, Psychopathology, n=34) finding 5-HTP 300 mg per day comparable to fluvoxamine 150 mg per day over 6 weeks on Hamilton Depression Rating Scale with fewer side effects. A Cochrane review by Shaw et al. (2002) identified 2 RCTs of sufficient quality, both showing 5-HTP superior to placebo, but concluded the evidence is insufficient for definitive conclusions pending larger trials. Evidence is most consistent in mild-to-moderate depression and is mechanistically plausible through serotonin deficiency models of depression, though effect magnitude and reliability remain less well established than SSRIs.
- • Appetite suppression and weight management: The appetite-suppressing mechanism is among the most mechanistically sound applications of 5-HTP. Three RCTs by Cangiano et al. at the University of Rome (1991, n=20; 1992, n=19; 1998, n=20) consistently found 5-HTP at 600 to 900 mg per day reduced self-reported daily caloric intake by 15 to 18 percent, with preferential reduction in carbohydrate intake through 5-HT2C receptor-mediated hypothalamic satiety signaling. Weight loss in these trials ranged from 1 to 2 kg more than placebo over 6 weeks without dietary instruction, suggesting a genuine pharmacological effect on appetite regulation independent of caloric restriction.
- • Anxiety and panic disorder: Serotonin dysfunction is implicated in anxiety disorders, and 5-HTP has been studied specifically for panic disorder and generalized anxiety. A double-blind trial by Schruers et al. (2002, European Neuropsychopharmacology, n=24) found 5-HTP significantly reduced the frequency and severity of CO2-induced panic attacks compared to placebo, with an effect size comparable to that of established anxiolytics in the same experimental paradigm. Multiple smaller studies support 5-HTP for anxiety symptoms in depression, consistent with the overlap of serotonin's roles in mood and anxiety regulation.
- • Sleep quality and insomnia: 5-HTP improves sleep quality through two complementary pathways: direct serotonergic modulation of sleep-wake circuits (serotonin in the dorsal raphe modulates slow-wave sleep initiation) and as the precursor to melatonin synthesis via N-acetylserotonin. Evening supplementation of 5-HTP at 100 to 300 mg has been reported in multiple smaller studies to reduce sleep onset latency, increase slow-wave sleep duration, and improve overall sleep quality as measured by polysomnography. A notable study by Bruni et al. (2004, European Journal of Pediatrics, n=45) found 5-HTP at 2 mg per kg per day significantly reduced sleep terrors in children compared to placebo over 20 weeks.
- • Migraine prevention: Serotonin dysregulation is central to migraine pathophysiology, and 5-HTP has been studied as a prophylactic agent. A 6-month RCT by Titus et al. (1986, Cephalalgia, n=48) found 5-HTP at 600 mg per day comparable to methysergide (a recognized migraine preventive) in reducing migraine frequency and severity with a more favorable side-effect profile. A meta-analysis by De Benedittis and Massei (1986) pooling 4 trials found 5-HTP reduced migraine attack frequency by 50 to 71 percent in responders. The mechanism involves serotonin-mediated modulation of trigeminovascular activation, the central process in migraine neurophysiology.
- • Fibromyalgia symptom management: Fibromyalgia is associated with reduced CSF levels of 5-HIAA (the main serotonin metabolite), suggesting serotonin deficiency as a contributing mechanism. A double-blind trial by Caruso et al. (1990, Journal of International Medical Research, n=50) found 5-HTP at 100 mg five times daily significantly reduced the number of tender points, intensity of pain, morning stiffness, sleep quality, and fatigue in fibromyalgia patients compared to placebo over 30 days, with 50 percent of 5-HTP patients rated as improved versus 20 percent placebo. Serotonin's role in descending pain modulation pathways provides the mechanistic basis for this effect.
- • Premenstrual dysphoric disorder (PMDD): Serotonin fluctuation across the menstrual cycle, with a relative serotonin trough during the late luteal phase, is a key pathophysiological mechanism in PMDD. 5-HTP supplementation in the luteal phase has been explored in small pilot studies as a way to maintain serotonin synthesis during the progesterone-dominant period when tryptophan hydroxylase activity may be reduced. While definitive RCT evidence specific to 5-HTP for PMDD is limited, the mechanistic alignment with SSRIs (the established PMDD treatment) supports its investigation and off-label use in carefully selected medication-free patients.
- • ADHD and attention (exploratory): Dopamine and norepinephrine are the primary neurotransmitter targets in ADHD pharmacotherapy, but serotonin plays a modulatory role in attention, impulsivity, and emotional regulation. Preliminary evidence from small open-label studies and case series suggests that 5-HTP supplementation may reduce impulsivity and emotional dysregulation symptoms in ADHD patients who have a component of serotonin dysfunction. The evidence base is insufficient to recommend 5-HTP as a first-line or adjunctive ADHD intervention, but it represents a biologically plausible mechanism for further investigation.
- • Post-stroke emotional dysregulation: Post-stroke depression affects approximately 30 percent of stroke survivors and is linked to disruption of serotonergic projections from the raphe nuclei. Small studies have examined 5-HTP supplementation in post-stroke emotional dysregulation, with some positive findings on depressive symptom scales. The evidence is not sufficient to recommend 5-HTP as a standard post-stroke intervention, but the mechanistic plausibility is established through the dependence of post-stroke depression recovery on serotonergic signaling.
Gene Interactions
Key Gene Targets
SLC6A4
SLC6A4 encodes the serotonin transporter (SERT), which is responsible for clearing synaptic serotonin back into the presynaptic neuron after release. 5-HTP supplementation increases serotonin synthesis and release, directly increasing the serotonin load that SERT must manage. In individuals with the SLC6A4 promoter short allele (5-HTTLPR S variant), SERT expression is reduced, resulting in slower serotonin clearance and potentially amplified serotonergic signaling when 5-HTP is supplemented, compared to long-allele (LL) homozygotes who have higher SERT expression and faster clearance.
Safety & Dosing
Contraindications
Concurrent use with MAOIs (monoamine oxidase inhibitors including phenelzine, selegiline, tranylcypromine, and dietary tyramine precautions): additive serotonin accumulation creates severe serotonin toxicity risk; absolutely contraindicated
Concurrent use with SSRIs or SNRIs without physician supervision: additive serotonergic load increases serotonin syndrome risk; requires careful dose titration and monitoring if combined
Concurrent use with triptans (sumatriptan, rizatriptan, etc.) for migraine: additive serotonergic stimulation increases serotonin syndrome risk, particularly with repeated triptan doses
Carcinoid tumor: 5-HTP supplementation markedly increases peripheral serotonin production, potentially exacerbating carcinoid syndrome symptoms including flushing, diarrhea, and bronchoconstriction
Systemic mastocytosis: mast cells store and release serotonin; conditions with mast cell activation may be worsened by increased serotonin precursor availability
Pregnancy and breastfeeding: insufficient safety data; theoretical concern about serotonin's roles in fetal development including vasoconstriction and platelet function
Drug Interactions
MAOIs (phenelzine, tranylcypromine, selegiline): absolutely contraindicated; combined MAOI-mediated serotonin degradation inhibition with 5-HTP-mediated serotonin synthesis increase creates life-threatening serotonin syndrome
SSRIs (fluoxetine, sertraline, paroxetine, citalopram): additive serotonin reuptake inhibition with increased serotonin synthesis; serotonin syndrome risk; combination requires physician supervision if used at all
SNRIs (venlafaxine, duloxetine): same mechanism as SSRIs; combination requires physician supervision
Triptans (sumatriptan, rizatriptan, eletriptan): additive 5-HT1B/1D and 5-HT1F agonism; serotonin syndrome risk with concurrent use
Tramadol: inhibits serotonin and norepinephrine reuptake and is a mu-opioid agonist; combination with 5-HTP increases serotonin syndrome risk
Linezolid and methylene blue: both are MAO inhibitors; combination with 5-HTP creates serious serotonin toxicity risk
Carbidopa (peripheral DDC inhibitor): actually a beneficial combination that reduces peripheral 5-HTP decarboxylation, improving CNS delivery and reducing GI side effects; used therapeutically in European clinical trials
St. John's Wort (hyperforin): serotonin reuptake inhibition by St. John's Wort combined with increased serotonin synthesis from 5-HTP; serotonin syndrome risk at higher doses of each
Common Side Effects
Nausea, vomiting, and GI discomfort are the most common side effects (occurring in 20 to 30 percent of users at doses above 300 mg per day) due to peripheral conversion to serotonin in the gut; starting at low doses (50 to 100 mg) and titrating slowly substantially reduces GI adverse effects
Drowsiness and sedation, particularly with evening dosing; may be a desired effect for sleep applications
Heartburn and gastric reflux related to peripheral serotonin effects on lower esophageal sphincter tone
Vivid or unusual dreams with evening dosing; attributed to serotonin effects on REM sleep architecture
Serotonin syndrome symptoms (restlessness, agitation, tremor, hyperthermia, clonus) if combined with serotonergic medications; a medical emergency requiring immediate discontinuation and medical evaluation
Studied Doses
Clinical trials have used doses ranging from 100 mg per day (for sleep and pediatric applications) to 900 mg per day (for obesity and appetite suppression in the Cangiano trials). Depression trials typically used 200 to 300 mg per day. Migraine prevention trials used 600 mg per day. Most trials are 4 to 12 weeks in duration. Long-term safety beyond 6 months has not been rigorously studied in controlled trials. The eosinophilia-myalgia syndrome (EMS) associated with L-tryptophan contamination in 1989 to 1990 has not been definitively linked to 5-HTP itself, but surveillance for peak-X contamination (an impurity found in some 5-HTP preparations) remains relevant in product quality assessment.
Mechanism of Action
Serotonin Precursor Loading and CNS Delivery
5-HTP exerts its pharmacological effects entirely through its role as the immediate precursor to serotonin. The normal rate-limiting step of serotonin synthesis is tryptophan hydroxylase-2 (TPH2) in the brain, which converts tryptophan to 5-HTP. TPH2 is subject to end-product feedback inhibition by serotonin itself and is also constrained by the availability of tryptophan in neurons, which depends on competition with other large neutral amino acids for transport via the L-type amino acid transporter 1 (LAT1/SLC7A5) at the blood-brain barrier. 5-HTP bypasses both limiting factors. Because 5-HTP is the product of the TPH-catalyzed reaction, it enters the serotonin synthesis pathway downstream of the feedback-regulated and transport-limited step, and it is transported across the blood-brain barrier through a mechanism that does not compete with other dietary amino acids. Once inside serotonergic neurons, 5-HTP is converted to serotonin by aromatic L-amino acid decarboxylase (AADC/DDC) using pyridoxal-5-phosphate (P5P) as the cofactor. The AADC decarboxylation step is rapid and not subject to the same feedback inhibition as TPH2, meaning that increasing 5-HTP delivery to neurons reliably increases serotonin synthesis. This makes 5-HTP a more direct and pharmacokinetically reliable serotonin precursor than tryptophan.
Peripheral Versus Central Serotonin Production
A critical pharmacokinetic challenge of 5-HTP supplementation is that AADC is ubiquitously expressed throughout the body, not only in serotonergic neurons. When 5-HTP is absorbed from the gut and enters the portal circulation, it is rapidly decarboxylated to serotonin by AADC in intestinal enterochromaffin cells, gut smooth muscle cells, and liver cells before it can reach the systemic circulation and eventually the CNS. This peripheral conversion has two clinical consequences: it reduces the fraction of 5-HTP that reaches the brain (limiting central serotonin augmentation), and it increases peripheral serotonin synthesis in the gut, which is responsible for the nausea, vomiting, and diarrhea that are the most common dose-limiting side effects of 5-HTP supplementation. Co-administration of carbidopa (a peripheral AADC inhibitor that does not cross the blood-brain barrier) substantially blocks this peripheral conversion, increasing the fraction of orally administered 5-HTP that reaches the CNS and reducing GI adverse effects. This is the pharmacological basis for the carbidopa plus 5-HTP combination used in some European clinical trials, which achieved antidepressant effects at lower total 5-HTP doses than monotherapy.
Melatonin Synthesis and Circadian Effects
Serotonin produced from 5-HTP in the pineal gland serves as the immediate precursor for melatonin synthesis through two sequential enzymatic steps: arylalkylamine N-acetyltransferase (AANAT) converts serotonin to N-acetylserotonin, and hydroxyindole-O-methyltransferase (HIOMT, also called ASMT) converts N-acetylserotonin to melatonin. This synthesis pathway is most active at night in response to darkness-induced norepinephrine release from the superior cervical ganglion, which stimulates AANAT transcription via beta-adrenergic receptors. Evening supplementation of 5-HTP increases the substrate availability for this pathway, potentially increasing melatonin production beyond the endogenous rate. This serotonin-to-melatonin biochemical link explains the sleep-promoting effects of 5-HTP and suggests that timing of supplementation (evening, 30 to 60 minutes before bed) maximizes the melatonin synthesis benefit.
Epigenetic Modulation
Serotonin serves as a substrate for serotonylation, a recently discovered epigenetic modification in which serotonin is covalently attached to glutamine residues on histone H3 (H3Q5) by transglutaminase 2 (TGM2). This histone serotonylation marks active enhancers and promoters and is recognized by the TFIID transcription factor complex, facilitating transcription of genes at serotonylated chromatin loci. This mechanism creates a direct link between cytoplasmic serotonin concentrations in neurons and epigenetic regulation of gene expression, suggesting that 5-HTP supplementation, by increasing serotonin availability, may influence the epigenetic landscape in serotonergic and serotonin-responsive cells. Additionally, serotonin modulates CREB (cAMP response element-binding protein) phosphorylation through 5-HT1A receptor-coupled signaling, influencing the expression of BDNF (brain-derived neurotrophic factor) and other plasticity genes that support synaptic remodeling in response to antidepressant treatment.
Clinical Evidence
Depression: Comparison with Standard Antidepressants
The most clinically relevant comparison studies for 5-HTP are those that placed it head-to-head against established antidepressants. The Poldinger et al. trial (1991, Psychopathology, PMID 1678245, n=34) compared 5-HTP 300 mg per day to fluvoxamine 150 mg per day over 6 weeks and found comparable reductions on the Hamilton Depression Rating Scale (HAMD) with 5-HTP showing numerically superior improvement on four of the five subscales. The Angst et al. multicenter trial (1977) compared 5-HTP to clomipramine (a tricyclic antidepressant) and found equivalent efficacy with substantially fewer anticholinergic side effects. The Cochrane review by Shaw et al. (2002, PMID 12519536) identified these as among the methodologically strongest available studies but noted that the overall evidence base falls short of modern regulatory standards for antidepressant claims. The clinical picture is consistent with 5-HTP having genuine antidepressant activity in mild-to-moderate depression with better tolerability than older tricyclic antidepressants, though the evidence is less extensive than for SSRIs.
Appetite Suppression: The Cangiano Trial Series
The most replicated clinical finding for 5-HTP is the appetite-suppressing effect demonstrated in the three Cangiano et al. trials (1991, 1992, 1998). Using a consistent methodology of measuring food intake with dietary records and food diaries in obese or overweight subjects without dietary restriction, these trials consistently found 5-HTP at 600 to 900 mg per day reduced daily caloric intake by 15 to 18 percent, with preferential reduction in carbohydrate consumption, and produced 1 to 2 kg more weight loss than placebo over 6 weeks. The 1992 trial used the most rigorous design with placebo-controlled crossover and electronic dietary intake recording. The mechanism, acting through hypothalamic 5-HT2C receptor-mediated satiety signaling on POMC neurons, is the same target as lorcaserin and other serotonergic weight-loss drugs, supporting the biological plausibility.
Fibromyalgia: A Serotonin-Deficiency Indication
Fibromyalgia patients have significantly lower cerebrospinal fluid levels of 5-HIAA, the main serotonin metabolite, compared to healthy controls, suggesting a functional central serotonin deficit. The Caruso et al. RCT (1990, Journal of International Medical Research, PMID 2193835, n=50) found 5-HTP at 100 mg five times daily (500 mg per day) significantly superior to placebo on a composite fibromyalgia assessment including tender point count (reduction of 2.8 versus 0.4 per group), pain visual analogue scale, morning stiffness rating, sleep quality, and fatigue, with a 50 percent responder rate versus 20 percent placebo. This application aligns well with the serotonin deficit hypothesis.
Dosing Guidance
The dosing range for 5-HTP varies considerably by indication. For depression and anxiety, 100 to 300 mg per day in two to three divided doses is the range used in trials. For appetite suppression, 300 mg taken 30 minutes before each main meal (900 mg total per day) was used in the Cangiano trials with the strongest evidence. For sleep promotion, 100 to 200 mg taken 30 to 60 minutes before bed is practical and well-tolerated. For migraine prevention, 600 mg per day in divided doses over sustained periods was studied. For fibromyalgia, 500 mg per day in divided doses matching the Caruso trial. All applications require initiating at 50 to 100 mg per day with gradual titration over 2 to 4 weeks to minimize GI adverse effects. The combination with carbidopa (50 mg peripheral DDC inhibitor) improves CNS delivery and reduces GI side effects but requires a prescription. Daily dosing above 900 mg is not supported by clinical evidence and increases adverse effect risk.
Getting the Most from 5-HTP
Always begin at the lowest practical dose (50 mg once daily) and increase every 5 to 7 days; the most common reason for 5-HTP discontinuation is GI side effects that could be largely avoided with slow titration
Disclose 5-HTP use to every prescriber before adding any new medication, particularly any psychiatric, pain, or migraine medication; the serotonin interaction profile is broad
For evening sleep support, take 100 to 200 mg approximately 30 to 60 minutes before bed; the melatonin precursor pathway provides additional benefit for sleep onset and circadian alignment
For appetite control, take 100 to 300 mg 30 minutes before each main meal on an empty stomach or with a light snack to trigger satiety signaling before caloric intake begins
Ensure adequate vitamin B6 (P5P) status, as AADC requires P5P as its cofactor; if supplementing both, take them together since P5P deficiency can limit the rate of 5-HTP to serotonin conversion
Consider a washout period of at least 2 weeks between stopping any SSRI or SNRI and initiating 5-HTP supplementation; the combination during the crossover period carries serotonin syndrome risk
For individuals with the SLC6A4 short allele (5-HTTLPR S variant) or known slow serotonin clearance, start at particularly low doses as the amplified serotonergic response increases both therapeutic potential and adverse effect risk
Rotate 5-HTP cycles (for example, 8 weeks on, 4 weeks off) to avoid potential depletion of upstream tryptophan stores and to reassess continued need; long-term continuous supplementation beyond 6 months lacks safety data
Product quality matters significantly for 5-HTP; select brands tested for peak-X contamination (an impurity found in some Griffonia seed extracts) through third-party certification
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Comprehensive clinical review synthesizing the evidence across depression, anxiety, fibromyalgia, headache, and obesity indications, providing the foundational summary of 5-HTP clinical trial data through the 1990s and establishing the rationale for 5-HTP as a versatile serotonin precursor supplement.
Double-blind RCT of 20 obese subjects finding 5-HTP at 900 mg per day significantly reduced daily caloric intake (by 15 percent) and carbohydrate intake preferentially over 6 weeks, with 1.8 kg more weight loss than placebo in the absence of dietary restriction, establishing the mechanistic basis for hypothalamic serotonin-mediated appetite suppression.
Early multicenter RCT comparing 5-HTP to the tricyclic antidepressant chlorimipramine (clomipramine) in depressed patients, finding equivalent antidepressant efficacy with substantially fewer anticholinergic side effects, one of the earliest demonstrations of 5-HTP clinical efficacy in a rigorous comparative trial.
Double-blind RCT comparing 5-HTP 300 mg per day with fluvoxamine 150 mg per day over 6 weeks in 34 depressed patients, finding comparable efficacy on Hamilton Depression Rating Scale with the 5-HTP group showing numerically superior improvement on most subscales and better tolerability, a key trial supporting 5-HTP as an SSRI-comparable intervention.
Reviews the evidence for 5-HTP in depression with a focus on the serotonin deficit hypothesis of depression, documenting that CSF 5-HIAA levels predict response to 5-HTP and that a subgroup of depressed patients with biochemical serotonin deficiency are particularly responsive to serotonin precursor supplementation.
Cochrane systematic review identifying 2 RCTs meeting quality standards for 5-HTP in depression, both showing superiority over placebo, while concluding that the evidence base requires larger modern trials for definitive recommendations, establishing the current state of the evidence and the methodological gaps in the 5-HTP depression literature.
Double-blind RCT of 50 fibromyalgia patients finding 5-HTP at 100 mg five times daily (500 mg per day) significantly superior to placebo for tender point count, pain intensity, morning stiffness, sleep quality, and fatigue over 30 days, with a 50 percent responder rate versus 20 percent placebo, the primary RCT supporting 5-HTP for fibromyalgia.
Systematic safety review of 5-HTP supplementation including analysis of peak-X contamination findings in commercial preparations, serotonin syndrome risk characterization, and dose-response safety data, providing the framework for safe use recommendations and quality control standards relevant to contemporary supplement use.
Foundational review of serotonin's roles in sleep architecture including the dorsal raphe serotonergic modulation of slow-wave sleep, NREM-REM transitions, and the biochemical pathway from serotonin to melatonin in the pineal gland, establishing the neurobiological basis for 5-HTP sleep promotion effects.